Geftib is a prescription medication that contains 250mg of Gefitinib, a tyrosine kinase inhibitor used in the treatment of various types of non-small cell lung cancer (NSCLC). It is available in tablet form.
Composition:
Geftib contains 250mg of Gefitinib, an off-white to pale yellow powder.
Mechanism of Action:
Gefitinib works by:
- Inhibiting the activity of epidermal growth factor receptor (EGFR) tyrosine kinase, which is a key protein involved in the growth and proliferation of cancer cells
- Inhibiting the activation of downstream signaling pathways, which leads to cell growth and survival
- Inducing apoptosis (cell death) in cancer cells
Indication:
Geftib is indicated for:
- First-line treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations
- Second-line treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations who have progressed on prior platinum-based chemotherapy
Dosage:
The recommended dosage of Geftib is:
- 250mg orally once daily, taken at the same time each day
- Dose adjustments may be necessary based on patient response and toxicity
Side Effects:
Common side effects of Geftib may include:
- Skin rash
- Diarrhea
- Fatigue
- Loss of appetite
- Nausea and vomiting
- Increased risk of infections
- Gastrointestinal toxicity (stomatitis, esophagitis)
- Pulmonary toxicity (pneumonitis)
Recommendation:
Geftib should only be used under the guidance of a healthcare provider. Patients receiving Geftib treatment should be closely monitored for side effects and potential complications.
Important Note:
- Geftib is a potent medication that can cause serious side effects, including pulmonary toxicity and skin rash. Patients should be closely monitored for these side effects.
- Patients with a history of severe allergic reactions to gefitinib or other tyrosine kinase inhibitors should not receive Geftib.
- Patients with a history of severe kidney disease or severe liver disease should be closely monitored while receiving Geftib.
Special Precautions:
- Patients with a history of severe respiratory disorders should be closely monitored while receiving Geftib.
- Patients with a history of bone marrow suppression or other bone marrow disorders should be closely monitored while receiving Geftib.
It is important to note that the dosage and administration of Geftib may vary depending on the patient’s individual needs and medical history. It is recommended that patients consult their healthcare provider before taking this medication.
Reviews
There are no reviews yet.